MedTrace Logo

ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

NCT01445600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3612

Last updated 2015-09-23

No results posted yet for this study

Summary

This is an open label, multi-centre, non-interventional post-marketing surveillance.

Conditions

  • Skin Infections, Bacterial

Interventions

DRUG

ALTARGO(retapamulin)

Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
9 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445600 on ClinicalTrials.gov